Study on Inhalable Parkinson’s Disease Medication
Researchers at Boston University Medical Campus are studying an investigational drug called CVT-301. The active ingredient in CVT-301 is levodopa, and is taken by using an inhaler, much like how asthma medication is inhaled. It is hoped that this will result in a more rapid relief of some Parkinson’s disease symptoms.
If you are taking Sinemet (Levodopa/Carbidopa) you may be eligible to participate in this study.
If you are interested in this study, please contact the researchers at Boston University Medical Center at 617-638-7745 or 617-638-7737 for more information.